Elicio Therapeutics ELTX 深 滬
等待開盤 11-04 09:30:00 美东时间
1.52
-0.070
-4.40%
華盛通- 最 高1.73
- 今 開1.71
- 成交量 51.71万股
- 最 低 1.445
- 昨 收 1.59
- 總市值 4117.86万
- 52周最高 16.00
- 市盈率 靜 --
- 換手率 1.91%
- 52周最低 1.44
- 委 比 -69.49%
- 總股本 2709.12万
- 歷史最高 263.00
- 量 比 2.14
- 振 幅 17.92%
- 歷史最低 1.44
- 每 手 1
- 風險率 3.82%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Elicio Therapeutics收跌5.36%，成交额53.7万美元
11月3日，Elicio Therapeutics（ELTX）收跌5.36%，报1.59美元，成交额53.7万美元，市值4307.5万美元。 行情数据 • 开盘...
11-03 08:26
Elicio Therapeutics收跌10.53%，成交额73.91万美元
10月27日，Elicio Therapeutics（ELTX）收跌10.53%，报1.7美元，成交额73.91万美元，市值4605.5万美元。 行情数据 •...
10-27 07:27
Elicio Therapeutics Presents Data From Its Phase 2 AMPLIFY-7P Trial Of Camupepimut At European Society For Medical Oncology Congress 2026
Elicio Therapeutics, Inc. (Nasdaq: ELTX) ("Elicio" or the "Company"), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced results from the randomized Phase 2 AMPLIFY-7P study of camupepimut (ELI-002 7P), presented in a late-break...
10-23 21:01
Elicio Therapeutics Presents Late-Breaking Phase 2 AMPLIFY-7P Results at ESMO Congress 2026 and Announces Simultaneous Publication in Nature Medicine
Elicio Therapeutics announced positive results from the Phase 2 AMPLIFY-7P trial of camupepimut (ELI-002 7P) in pancreatic cancer. The study showed favorable disease-free survival (DFS) outcomes in both ctDNA-negative (HR 0.51) and ctDNA-positive (HR 0.57) patients, despite not meeting the primary DFS endpoint in the intent-to-treat population (HR 0.85). Baseline ctDNA positivity was more prevalent in the camupepimut arm, highlighting prognostic ...
10-23 13:00
Elicio Therapeutics收跌12.36%，成交额55.27万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 07:33
美股大行评级 | Meta获4家机构齐升目标价，最高看至995美元！麦当劳遭6家机构下调，最低看至260美元
今日重点评级关注：Canaccord Genuity：维持Aurora Innovation"买入"评级，目标价从15美元升至17美元；摩根大通：维持皇家加勒比邮轮"超配"评级，目标价从345美元升至394美元
09-25 15:55
B. Riley Securities Maintains Buy on Elicio Therapeutics, Lowers Price Target to $8
B. Riley Securities analyst Mayank Mamtani maintains Elicio Therapeutics (NASDAQ:ELTX) with a Buy and lowers the price target from $27 to $8.
09-24 22:16
Elicio Therapeutics Announces Late-Breaking Phase 2 AMPLIFY-7P Data Selected for Proffered Paper Oral Presentation at ESMO Congress 2026
Elicio Therapeutics announced new pre-specified analyses from its Phase 2 AMPLIFY-7P study of ELI-002 7P in pancreatic ductal adenocarcinoma (PDAC), to be presented as a late-breaking Proffered Paper at the ESMO Congress 2026 in Madrid. The findings aim to refine the Phase 3 development strategy for adjuvant pancreatic cancer treatment. Despite not meeting the primary disease-free survival endpoint, the study provided insights into ELI-002 7P's c...
09-24 12:00
Elicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference
Elicio Therapeutics, a clinical-stage biotech company developing immunotherapies for KRAS-driven cancers, announced that its management will participate in one-on-one meetings at the Wells Fargo 21st Annual Healthcare Conference on September 10, 2026, in Boston. The company focuses on off-the-shelf immunotherapy candidates targeting common cancer mutations, including KRAS, BRAF, and p53, aiming for rapid manufacturing and patient access. For more...
08-24 12:00
美股大行评级 | 潜在涨幅167.3%！HC Wainwright上调Tango Therapeutics目标价至68美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Tango Therapeutics"买入"评级，目标价从66美元升至68美元；康托·菲茨杰拉德：维持Duos Technologies Group"超配"评级，目标价从26美元升至27美元
08-19 08:37
